focusing on cancer indications with the greatest medical need for new treatments
Featured News & Events
Sept 8, 2021
Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival
Sept 7, 2021
Cardiff Oncology to Present at Upcoming Investor Conferences in September
Aug 25, 2021
Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer on September 8, 2021
Our Clinical Programs
KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
Combining onvansertib with FOLFIRI/Avastin® to improve efficacy by increasing duration of response and overall survival.
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Leveraging the synergy of onvansertib to increase duration and response of overall survival.
Zytiga-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Adding onvansertib to daily Zytiga® to overcome resistance, extend treatment response and overall survival.